Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03409614 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | PHASE3 | COMPLETED | 789 | — | — | Mar 6, 2018 | Feb 27, 2025 | May 18, 2026 | 133 | United States, Austria +16 |
OS was defined as the time from randomization to the date of death due to any cause.
OS was defined as the time from randomization to the date of death due to any cause.
| Arm | Type | Description |
|---|---|---|
| Chemo | OTHER | Part 1: Chemotherapy |
| REGN2810+Chemo Part 1 | EXPERIMENTAL | Part 1: REGN2810+chemo |
| REGN2810+AbbrevChemo+ipi | EXPERIMENTAL | Part 1: REGN2810+abbrev chemo+ipi |
| Placebo+Chemo | EXPERIMENTAL | Part 2: Placebo plus chemo |
| REGN2810+Chemo Part 2 | EXPERIMENTAL | Part 2: REGN2810+chemo |
| Name | Type | Description |
|---|---|---|
| REGN2810 | DRUG | REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2 |
| REGN2810/chemo/ipi | DRUG | REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1 |
| Chemotherapy | OTHER | Platinum-based doublet chemotherapy Part 1 |
| Placebo | DRUG | Matching placebo Part 2 |
Key Inclusion Criteria: 1. Men and women ≥20 years of age for Japanese patients 2. Patients with histologically or cytologically documented squamous or non-squamous NSCLC with stage IIIB or IIIC disease who are not candidates for treatment with definitive concurrent chemoradiation or patients with ...